Fact checked by Jennifer Klump Key Takeaways The FDA approved the obesity drug Wegovy as a treatment for people with MASH ...

In other recent news, Madrigal Pharmaceuticals has received European Commission approval for its MASH treatment, Rezdiffra, marking it as the first approved medication for this liver condition in the ...

Promethera is a Belgian biotech company developing stem cell therapies for the treatment of inborn liver metabolic diseases and acquired liver diseases with high unmet medical needs. It is a spin-off ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it ...

Wegovy is now the second medicine approved in the U.S. for a disease that affects millions. Novo Nordisk has several other ...

Conshohocken, Pennsylvania Thursday, August 21, 2025, 14:00 Hrs [IST] ...

Madrigal Pharmaceuticals MDGL announced that the European Commission (EC) has granted a conditional marketing authorization ...

Investing.com - Madrigal Pharmaceuticals (NASDAQ:MDGL) stock gained Wednesday after the European Commission approved its MASH treatment REZDIFFRA, making it the first approved medication for this ...

Madrigal Pharmaceuticals ( NASDAQ: MDGL) has received conditional marketing approval from the European Commission for ...

The European Commission (EC) has granted conditional marketing authorization for Madrigal Pharmaceuticals' Rezdiffra (resmetirom) for the treatment of adults with noncirrhotic metabolic ...